Coral Laboratories Peer Comparison

BSE: 524506

₹486.20

₹-12.80 (-2.57%)

As on 04-Nov-2026IST

Market cap

₹174 Cr

Revenue (TTM)

₹97 Cr

P/E Ratio

P/B Ratio

0.8

Div. Yield

0.4 %

Edit

	Coral Laboratories	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Market cap (₹ Cr)	174	18,234	18,365	17,532	16,891
Revenue (₹ Cr)	97	1,682	2,287	2,654	3,330
Net Profit (₹ Cr)	19.21	273.51	678.07	859.38	720.77
Net Margin (%)	18.00	16.19	28.10	30.42	21.60
RoE (%)	8.98	11.15	19.73	18.58	18.93
Price to Earnings	9.04	61.33	27.60	20.40	23.87
Price-To-Book	0.81	6.79	5.00	3.98	4.08

Income Statement (₹ Cr)

	Coral Laboratories	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Operating Revenue	96.70	1,682.47	2,287.33	2,654.29	3,329.63
Total Income	106.70	1,689.83	2,413.29	2,825.39	3,337.47
Total Expenditure	78.18	1,203.91	1,490.75	1,681.39	2,168.88
EBITDA	18.52	478.55	796.58	972.90	1,160.75
Depreciation	2.35	126.01	78.10	57.71	285.40
EBIT	16.17	352.55	718.48	915.19	875.35
Interest	0.15	52.11	0.88	8.91	187.51
Other Income	10.00	7.37	125.96	171.10	7.84
Exceptional Items	0.31	12.16	0.00	82.90	-53.14
Profit before Tax	26.34	319.96	843.56	1,160.28	642.54
Provision for Tax	7.13	46.45	165.49	300.90	-78.23
Profit after Tax	19.21	273.51	678.07	859.38	720.77

	Coral Laboratories	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Shareholder's Funds	209.12	2,591.20	3,586.42	4,385.41	4,144.34
Minority Interest	0.00	0.00	-12.71	0.00	-10.85
Non-Current Liabilities	4.24	266.35	28.74	222.21	758.48
Current Liabilities	27.31	848.06	385.94	685.36	2,681.14
Total Liabilities	240.66	3,705.61	4,037.51	4,921.88	7,246.72

	Coral Laboratories	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Non-Current Assets	61.30	2,525.44	1,291.22	905.21	5,578.78
Current Assets	176.97	1,109.77	2,585.66	4,024.56	1,800.86
Total Assets	240.66	3,705.61	4,037.51	4,921.88	7,246.72
Total Debt*	4.33	657.97	0.57	2.50	2,309.68
Net Current Assets	149.66	261.71	2,199.72	3,339.20	-880.28
Contingent Liabilities	--	160.01	17.53	370.49	51.57

	Coral Laboratories	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Cash From Operating Activities	15.62	342.18	523.24	967.57	537.99
Cash Flow from Investing Activities	-17.71	-325.92	-582.30	-561.67	-369.46
Cash from Financing Activities	0.06	13.62	-46.46	-798.31	-313.53
Net Cash Inflow / Outflow	-2.03	29.88	-105.52	-392.41	-145.00

	Coral Laboratories	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
ROCE (%)	11.14	11.43	24.97	23.39	14.47
ROE (%)	8.98	11.15	19.73	18.58	18.93
ROA (%)	8.17	7.80	18.69	17.36	9.78
EBIT Margin (%)	16.72	20.95	31.41	34.48	26.29
Net Margin (%)	18.00	16.19	28.10	30.42	21.60
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Coral Laboratories	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Revenue Growth (%)	-5.35	27.91	15.01	11.75	11.06
EBIT Growth (%)	2.90	58.32	18.45	21.45	13.71
Net Profit Growth (%)	7.21	149.56	19.61	2.39	60.98
EPS Growth (%)	2.59	-3.57	17.73	13.17	80.38
Book Value Growth (%)	3.93	9.67	26.75	-0.34	36.71

	Coral Laboratories	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Price / Earnings	9.16	65.06	27.60	21.98	22.11
Price / Book Value	0.81	6.79	5.00	3.98	4.08
Dividend Yield (%)	0.41	0.06	0.33	1.96	0.00
EV/EBITDA	4.11	39.38	21.79	14.83	16.48
Market Cap (₹ Cr)	132.38	6,819.66	11,439.22	21,592.90	17,980.08

	Coral Laboratories	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Debt to Equity	0.00	0.07	0.00	0.00	0.10
Short term debt to equity ratio	0.02	0.16	0.00	0.00	0.12
Current Ratio	6.48	1.31	6.70	5.87	0.67
Quick Ratio	5.73	0.88	5.59	5.23	0.49
Interest Coverage	182.66	7.14	959.59	131.22	4.43

	Coral Laboratories	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Debtors to sales (%)	30.43	30.84	36.10	9.10	18.98
Asset Turnover	0.41	0.48	0.63	0.54	0.45
Receivable days	134.00	113.81	121.68	26.06	63.88
Inventory Days	64.59	84.76	63.83	65.95	43.27
Payable days	146.86	101.94	108.28	81.01	151.85
Cash Conversion Cycle	51.73	96.62	77.23	11.00	-44.70

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.